BIO
Bio-Rad Laboratories, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
+18/100
Last price
358.97
▼ 20.85 (5.49%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
383.38
Prev close
379.82
Day high
389.88
Day low
367.49
Volume
162.23K
Market cap
$9.86B
P/E (TTM)
46.75
52W range
236.73 – 396.23
Day trading desk
Gap from prior close
+0.94%
Prior close 379.82
VWAP
370.98
-3.24% from price
Relative volume
1.24×
Normal
Session range
8.64%
358.97 – 390.00
Position in range
0%
Near session low
ATR (14D)
12.21
3.40% of price
Prior day high
381.78
PDH
Prior day low
363.96
PDL
Bid / ask spread
—
Quote not published
Session volume
342.42K
Avg 276.94K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.82%
-4.8%
1M
-4.48%
-5.6%
3M
+29.93%
+25.4%
6M
+32.67%
+14.5%
YTD
+21.73%
+7.5%
1Y
+20.73%
+4.3%
3Y
+2.90%
-79.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BIO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+30.15K
Net buying
Buy transactions
19
30.70K shares
Sell transactions
1
550 shares
Net transactions
+20
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
4.39M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 4, 26 | SCHWARTZ NORMAN D Chief Executive Officer |
— | 7.56K | — | Direct |
| Sep 4, 26 | LAKKARAJU ROOP KALYAN Chief Financial Officer |
— | 2.91K | — | Direct |
| Sep 4, 26 | ALLISON SCHWARTZ Director |
— | 320 | — | Direct |
| Sep 4, 26 | EVRAN SEDAT Officer |
— | 1.89K | — | Direct |
| Sep 4, 26 | DIVINCENZO JONATHAN P President |
— | 1.71K | — | Direct |
| Sep 4, 26 | ENLOE COURTNEY C General Counsel |
— | 1.45K | — | Direct |
| Sep 4, 26 | BARRY JAMES Officer |
— | 2.08K | — | Direct |
| Sep 4, 26 | ENGELHARDT EVA ANETTE Officer |
— | 2.18K | — | Direct |
| Sep 4, 26 | MEHTA RAJAT Officer |
— | 1.83K | — | Direct |
| Sep 1, 26 | SCHWARTZ NORMAN D Chief Executive Officer |
— | 5.09K | — | Direct |
| Sep 1, 26 | ALLISON SCHWARTZ Director |
— | 117 | — | Direct |
| Sep 1, 26 | BARRY JAMES Officer |
— | 425 | — | Direct |
| Jul 24, 26 | ENGELHARDT EVA ANETTE Officer |
— | 246 | — | Direct |
| May 11, 26 | ENGELHARDT EVA ANETTE Officer |
SELL | 550 | $135.60K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALLISON SCHWARTZ |
Director | 1.73K | Conversion of Exercise of derivative security |
BARRY JAMES |
Officer | 2.02K | Conversion of Exercise of derivative security |
COREY COLLEEN |
Officer | 19.55K | Conversion of Exercise of derivative security |
CROWLEY MICHAEL W |
Officer | 8.17K | Conversion of Exercise of derivative security |
DIVINCENZO JONATHAN P |
President | 1.96K | Conversion of Exercise of derivative security |
ENGELHARDT EVA ANETTE |
Officer | 1.83K | Conversion of Exercise of derivative security |
ENLOE COURTNEY C |
General Counsel | 1.65K | Conversion of Exercise of derivative security |
EVRAN SEDAT |
Officer | 3.60K | Conversion of Exercise of derivative security |
LAKKARAJU ROOP KALYAN |
Chief Financial Officer | 4.15K | Conversion of Exercise of derivative security |
SCHWARTZ NORMAN D |
Chief Executive Officer | 3.16M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$9.86B
Enterprise value$9.61B
Revenue (TTM)$2.59B
Gross profit$1.35B
EBITDA$441.00M
Net income$222.40M
EPS (TTM)$7.89
Free cash flow$283.19M
Total cash$1.62B
Total debt$1.37B
Book value / share$268.30
Shares outstanding21.68M
Float21.35M
Short % of float6.28%
Dividend yield0.00%
Beta (5Y)1.07
Valuation & profitability ratios
Trailing P/E46.75
Forward P/E37.19
PEG ratio4.01
Price / sales—
Price / book1.37
EV / revenue3.71
EV / EBITDA21.80
Gross margin52.04%
Operating margin11.18%
Profit margin8.59%
Return on equity3.11%
Return on assets1.66%
Debt / equity19.10
Current ratio3.14
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.58B | $2.57B | $2.67B | $2.80B | +0.7% |
| Operating revenue | $2.58B | $2.57B | $2.67B | $2.80B | +0.7% |
| Cost of revenue | $1.24B | $1.19B | $1.24B | $1.23B | +4.7% |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | -2.8% |
| Research & development | $275.60M | $295.90M | $247.40M | $256.90M | -6.9% |
| Selling, general & admin | $844.30M | $814.00M | $841.70M | $827.80M | +3.7% |
| Total operating expense | $1.12B | $1.11B | $1.09B | $1.09B | +1.0% |
| Operating income | $218.60M | $269.00M | $337.80M | $475.10M | -18.7% |
| Net interest income | $46.50M | $33.10M | $51.50M | $20.00M | +40.5% |
| Pre-tax income | $995.50M | -$2.34B | -$850.10M | -$4.70B | +142.5% |
| Tax provision | $235.60M | -$498.30M | -$212.80M | -$1.08B | +147.3% |
| Net income | $759.90M | -$1.84B | -$637.30M | -$3.63B | +141.2% |
| Net income to common | $759.90M | -$1.84B | -$637.30M | -$3.63B | +141.2% |
| Basic EPS | 27.87 | -65.36 | -21.82 | -121.79 | +142.6% |
| Diluted EPS | 27.85 | -65.36 | -21.82 | -121.79 | +142.6% |
| EBIT | $1.04B | -$2.29B | -$800.70M | -$4.67B | +145.5% |
| EBITDA | $1.21B | -$2.14B | -$654.80M | -$4.53B | +156.5% |
| Basic shares | 27.26M | 28.21M | 29.21M | 29.79M | -3.4% |
| Diluted shares | 27.28M | 28.21M | 29.21M | 29.79M | -3.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $529.80M | $488.10M | $403.80M | $434.21M | +8.5% |
| Cash & short-term investments | $1.54B | $1.66B | $1.61B | $1.79B | -7.4% |
| Accounts receivable | $460.60M | $452.50M | $489.00M | $494.64M | +1.8% |
| Inventory | $740.70M | $760.00M | $780.50M | $719.32M | -2.5% |
| Total current assets | $2.91B | $3.03B | $3.05B | $3.16B | -4.1% |
| Property, plant & equipment | $709.90M | $688.60M | $723.70M | $679.55M | +3.1% |
| Goodwill & intangibles | $754.10M | $704.10M | $734.10M | $738.60M | +7.1% |
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | +12.9% |
| Total current liabilities | $517.00M | $467.80M | $522.80M | $568.71M | +10.5% |
| Current debt | $1.30M | $1.20M | $500.00K | $465.00K | +8.3% |
| Long-term debt | $1.20B | $1.20B | $1.20B | $1.20B | +0.2% |
| Total debt | $1.39B | $1.37B | $1.41B | $1.39B | +0.8% |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | +11.7% |
| Retained earnings | $8.18B | $7.42B | $9.26B | $9.90B | +10.2% |
| Shareholder equity | $7.45B | $6.57B | $8.74B | $9.62B | +13.5% |
| Working capital | $2.39B | $2.56B | $2.53B | $2.59B | -6.8% |
| Net tangible assets | $6.70B | $5.87B | $8.01B | $8.88B | +14.2% |
| Shares issued | 30.27M | 30.27M | 30.27M | 30.24M | -0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $759.90M | -$1.84B | -$637.30M | -$3.63B | +141.2% |
| Depreciation & amortisation | $165.40M | $151.60M | $145.90M | $137.30M | +9.1% |
| Stock-based compensation | $58.00M | $62.30M | $61.30M | $60.90M | -6.9% |
| Change in working capital | $272.40M | -$620.80M | -$432.80M | -$1.61B | +143.9% |
| Operating cash flow | $532.20M | $455.20M | $374.90M | $194.40M | +16.9% |
| Capital expenditure | -$157.60M | -$189.00M | -$156.70M | -$114.30M | +16.6% |
| Investing cash flow | -$189.70M | -$160.20M | $20.20M | -$1.21B | -18.4% |
| Share buybacks | -$295.50M | -$203.60M | -$428.70M | -$215.70M | -45.1% |
| Financing cash flow | -$283.20M | -$218.80M | -$425.60M | $973.60M | -29.4% |
| Free cash flow | $374.60M | $266.20M | $218.20M | $80.10M | +40.7% |
| End cash position | $532.20M | $489.80M | $404.40M | $434.50M | +8.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $651.00M | $592.10M | $693.20M | $653.00M | $651.60M | +9.9% |
| Operating revenue | $651.00M | $592.10M | $693.20M | $653.00M | $651.60M | +9.9% |
| Cost of revenue | $305.20M | $282.70M | $348.00M | $309.60M | $306.30M | +8.0% |
| Gross profit | $345.80M | $309.40M | $345.20M | $343.40M | $345.30M | +11.8% |
| Research & development | $61.20M | $62.90M | $70.30M | $71.30M | $60.50M | -2.7% |
| Selling, general & admin | $212.00M | $212.40M | $221.00M | $206.80M | $207.70M | -0.2% |
| Total operating expense | $273.20M | $275.30M | $291.30M | $279.50M | $268.20M | -0.8% |
| Operating income | $72.60M | $34.10M | $53.90M | $63.90M | $77.10M | +112.9% |
| Net interest income | $10.20M | $8.70M | $18.90M | $1.40M | $2.10M | +17.2% |
| Pre-tax income | $542.10M | -$689.80M | $929.20M | -$431.10M | $414.00M | +178.6% |
| Tax provision | $170.70M | -$162.70M | $209.20M | -$89.20M | $96.20M | +204.9% |
| Net income | $371.40M | -$527.10M | $720.00M | -$341.90M | $317.80M | +170.5% |
| Net income to common | $371.40M | -$527.10M | $720.00M | -$341.90M | $317.80M | +170.5% |
| Basic EPS | 13.89 | -19.55 | 26.69 | -12.70 | 11.67 | +171.0% |
| Diluted EPS | 13.85 | -19.55 | 26.65 | -12.70 | 11.67 | +170.8% |
| EBIT | $554.20M | -$677.50M | $941.30M | -$418.80M | $426.60M | +181.8% |
| EBITDA | $595.30M | -$636.60M | $983.80M | -$374.60M | $467.20M | +193.5% |
| Basic shares | 26.75M | 26.96M | 26.98M | 26.92M | 27.23M | -0.8% |
| Diluted shares | 26.81M | 26.96M | 27.01M | 26.92M | 27.23M | -0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $517.00M | $507.20M | $529.80M | $395.80M | $369.30M | +1.9% |
| Cash & short-term investments | $1.62B | $1.56B | $1.54B | $1.42B | $1.37B | +3.4% |
| Accounts receivable | $441.80M | $426.20M | $460.60M | $464.70M | $469.90M | +3.7% |
| Inventory | $780.60M | $770.50M | $740.70M | $783.20M | $798.80M | +1.3% |
| Total current assets | $3.02B | $2.94B | $2.91B | $2.84B | $2.81B | +2.7% |
| Property, plant & equipment | $671.90M | $689.40M | $709.90M | $720.50M | $740.10M | -2.5% |
| Goodwill & intangibles | $734.30M | $743.90M | $754.10M | $967.10M | $978.50M | -1.3% |
| Total assets | $10.25B | $9.79B | $10.58B | $9.70B | $10.21B | +4.7% |
| Total current liabilities | $961.30M | $917.00M | $517.00M | $522.30M | $548.90M | +4.8% |
| Current debt | $400.70M | $400.50M | $1.30M | $1.30M | $1.30M | +0.0% |
| Long-term debt | $803.00M | $802.90M | $1.20B | $1.20B | $1.20B | +0.0% |
| Total debt | $1.37B | $1.38B | $1.39B | $1.40B | $1.41B | -0.6% |
| Total liabilities | $3.08B | $2.94B | $3.12B | $2.96B | $3.09B | +4.7% |
| Retained earnings | $8.02B | $7.65B | $8.18B | $7.46B | $7.80B | +4.9% |
| Shareholder equity | $7.17B | $6.85B | $7.45B | $6.74B | $7.13B | +4.7% |
| Working capital | $2.06B | $2.03B | $2.39B | $2.32B | $2.26B | +1.7% |
| Net tangible assets | $6.44B | $6.11B | $6.70B | $5.77B | $6.15B | +5.4% |
| Shares issued | 26.74M | 30.27M | 30.27M | 30.27M | 30.27M | -11.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $371.40M | -$527.10M | $720.00M | -$341.90M | $317.80M | +170.5% |
| Depreciation & amortisation | $41.10M | $40.90M | $42.50M | $44.20M | $40.60M | +0.5% |
| Stock-based compensation | $14.50M | $15.00M | $15.90M | $14.90M | $11.90M | -3.3% |
| Change in working capital | $138.40M | -$168.50M | $254.10M | -$102.40M | $77.10M | +182.1% |
| Operating cash flow | $98.70M | $108.10M | $164.90M | $120.90M | $116.50M | -8.7% |
| Capital expenditure | -$32.00M | -$30.00M | -$45.80M | -$31.70M | -$45.70M | -6.7% |
| Investing cash flow | -$66.70M | -$93.20M | -$34.20M | -$43.00M | -$115.40M | +28.4% |
| Share buybacks | -$31.50M | -$47.80M | $0 | -$53.40M | -$140.20M | +34.1% |
| Financing cash flow | -$27.60M | -$44.00M | $3.30M | -$52.50M | -$136.30M | +37.3% |
| Free cash flow | $66.70M | $78.10M | $119.10M | $89.20M | $70.80M | -14.6% |
| End cash position | $518.80M | $509.00M | $532.20M | $398.20M | $371.70M | +1.9% |
Options analytics
Put / call volume
0.02
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
290.00
-21.4% from spot
ATM implied vol
0.4%
Nearest strike to spot
Skew (10% OTM)
-6.2%
Calls bid over puts
Call volume
534
Contracts, this expiry
Put volume
10
Contracts, this expiry
Heaviest call OI
290.00
0 contracts
Heaviest put OI
350.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.75 | 2.62 | +50.1% |
| Mar 2026 | 1.99 | 1.89 | -4.8% |
| Dec 2025 | 2.70 | 2.51 | -7.0% |
| Sep 2025 | 1.93 | 2.26 | +17.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.23 | 2 | $649.95M | -0.5% |
| Next quarter | 3.02 | 2 | $695.40M | +0.3% |
| Current year | 9.45 | 3 | $2.57B | -0.5% |
| Next year | 9.92 | 3 | $2.62B | +2.1% |
Analyst targets & ownership
Mean target$328.33
High target$390.00
Low target$280.00
Implied upside-8.53%
Analyst count3
ConsensusHOLD
Strong buy / Buy1 / 0
Hold1
Sell / Strong sell0 / 1
Held by insiders16.41%
Held by institutions91.55%
Institutions holding529
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
375.57
-4.42% from price
SMA 20
375.60
-1.80% from price
SMA 50
368.00
+0.23% from price
SMA 100
331.06
+8.43% from price
SMA 200
308.45
+19.58% from price
EMA 12
374.33
-4.10% from price
EMA 26
373.43
-3.87% from price
EMA 50
362.65
-1.02% from price
RSI (14)
47.4
Neutral
MACD (12,26,9)
0.90
Hist -2.14
ATR (14)
12.21
3.31% of price
Realised vol 30D
29.8%
Annualised
Bollinger upper
389.28
20, 2σ
Bollinger lower
361.93
20, 2σ
50 / 200 cross
Golden
368.00 vs 308.45
Trend bias
Above 200
+19.58%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.72
Less volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
29.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.9%
Peak to trough
Max drawdown 5Y
-72.7%
Peak to trough
ATR 14
12.21
3.31% of price
Beta (reported)
1.07
5Y monthly, from filing
Short interest
Shares short
998.65K
Prior 1.33M
Change vs prior
-24.8%
Shorts covering
% of float
6.28%
Normal
% of shares out
3.73%
Against total outstanding
Days to cover
3.8
Liquid
Float
21.35M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 5, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Aug 5, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 5, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| May 1, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Apr 7, 26 | Citigroup | DOWNGRADE | Buy | Neutral |
| Feb 16, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Oct 30, 25 | Citigroup | MAINTAINED | Buy | Buy |
| Oct 30, 25 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 1, 25 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 1, 25 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Jun 9, 25 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split2:1
Split dateMar 8, 2002
SEC filings
Periodic Financial Reports
10-Q · 2026-08-04
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-13
Periodic Financial Reports
10-Q · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-04-24
Annual Report to Shareholders
ARS · 2026-03-25
Corporate Changes & Voting Matters
8-K · 2026-02-19
Periodic Financial Reports
10-K · 2026-02-13
Corporate Changes & Voting Matters
8-K · 2026-02-12
Headlines
Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates
Zacks · 9h ago
Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption
GlobeNewswire · 6d ago
Why Bio Rad Laboratories (BIO) Is Back In The Spotlight
Simply Wall St. · 6d ago
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
Zacks · 9d ago
Magnetic Beads - Global Strategic Business Report: Capitalize on the Surge from $3.3 Billion in 2025 to $7.4 Billion by 2032 as Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories and Miltenyi Biotec Battle for Leadership
GlobeNewswire · 9d ago
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
MarketBeat · 11d ago
Cell Isolation/Cell Separation Market Forecasts Growth from $6.97B (2026) to $13.51B by 2032, Profiling Thermo Fisher, Bio-Rad, Beckman Coulter & Sartorius
GlobeNewswire · 13d ago
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
InvestorsHub · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.